Drug Profile

KH 607

Alternative Names: KH-607

Latest Information Update: 07 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chengdu Kanghong Pharmaceutical
Class Antidepressants
Mechanism of Action GABA A receptor positive allosteric modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Major depressive disorder

Most Recent Events

03 Aug 2025 Chengdu Kanghong Pharmaceutical Group plans phase II trial in Major depressive disorder (PO) in August 2025 (NCT07101120)
31 Jul 2025 Chengdu Kanghong Pharmaceutical plans a phase II trial for Postnatal depression (PO, Tablet) in July 2025 (NCT07096791)
17 May 2025 Pharmacodynamic, pharmacokinetic and safety data from a preclinical study in depression presented at the 178th Annual Meeting of the American Psychiatric Association (APA 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com